Cardiovascular risk and sodium-glucose cotransporter 2 inhibition in type 2 diabetes

New England Journal of Medicine

Volumn 373, Issue 22, 2015, Pages 2178-2179

  Ingelfinger, Julie R ^a   Rosen, Clifford J ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Clinical and Translational Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; GLUCOSE TRANSPORTER; GLYCOSYLATED HEMOGLOBIN; INSULIN; PLACEBO; SODIUM; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); EDITORIAL; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; KIDNEY BLOOD FLOW; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SODIUM BALANCE; SODIUM TRANSPORT; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; MALE;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE;

EID: 84948432337     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1512602     Document Type: Editorial

References (7)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
2. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-28.
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117-28.
4. Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodiumglucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol 2015 September 9 (Epub ahead of print).
5. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 2015; 66: 255-70.
6. Marsenic O. Glucose control by the kidney: An emerging target in diabetes. Am J Kidney Dis 2009; 53: 875-83.
7. Chasis H, Jolliffe N, Smith HW. The action of phlorizin on the excretion of glucose, 643 xylose, sucrose, creatinine, and urea by man. J Clin Invest 1933; 12: 1083-90.